FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/07/2023
Back to search
Official data from USPTO
APEXP
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
08/07/2023
Trademark type
Word
Nice classes
9, 42
Filing date
09/27/2021
Registration date
03/28/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/28/2023
Last transaction
03/28/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
16
Owner location
ES
Examiner
MESSICK, TABITHA LEE
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
T. S. (pessoa física)
Representatives
John G. Tutunjian Tutunjian & Bitetto, P.C.
Technical classification
Nice Classes
Class 9Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 9
Downloadable software for the research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; downloadable computer software platforms for the research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; downloadable computer software using artificial intelligence for the research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; downloadable computer software platforms using artificial intelligence for the research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria
Class 42
Software as a service (SaaS) services featuring software for the research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; software as a service (SaaS) services featuring artificial intelligence software for the research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; platform as a service (PaaS) services featuring software platforms for the research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; platform as a service (PaaS) services featuring software platforms using artificial intelligence for the research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; biomedical research services; scientific research for medical purposes in the field of infectious diseases and diseases caused by bacteria; research and development of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria; conducting clinical trials for others of pharmaceutical compositionspharmaceutical productsdiagnostic reagentsantibioticsbiomarkersenzymes and synthetic proteins in the field of infectious diseases and diseases caused by bacteria
Publications
History of USPTO decisions and trademark events.
30 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/18/2023
FIMP
FINAL DISPOSITION PROCESSED
07/18/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/28/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/28/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
03/28/2023
GPNX
NOTIFICATION PROCESSED BY IB
01/24/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/10/2023
PUBO
PUBLISHED FOR OPPOSITION
01/10/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/04/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/04/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/21/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/02/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/17/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/16/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/16/2022
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
10/19/2022
ATRV
ATTORNEY REVIEW COMPLETED
10/06/2022
LIME
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
10/06/2022
RFNT
REFUSAL PROCESSED BY IB
08/23/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/29/2022
RFRR
REFUSAL PROCESSED BY MPU
07/29/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/03/2022
CNRT
NON-FINAL ACTION WRITTEN
07/02/2022
DOCK
ASSIGNED TO EXAMINER
06/28/2022
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
06/20/2022
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
05/29/2022
MAFR
APPLICATION FILING RECEIPT MAILED
11/23/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/19/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/18/2021
Continuous trademark protection
Get notified about every new filing that threatens APEXP or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.